J&J reports Phase II PFS and OS data for FGFR inhibitor in urothelial cancer

Johnson & Johnson (NYSE:JNJ) reported data from 99 evaluable patients with urothelial cancer in the Phase II BLC2001 trial showing that once-daily erdafitinib (JNJ-42756493)

Read the full 240 word article

User Sign In